Sandoz vs. Boehringer-Ingelheim: Federal Court Affirms Non-Infringement in Nintedanib Patent Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Sandoz, Inc. v. Boehringer Ingelheim Pharmaceuticals Inc., et al. |
| Case Number | 1:24-cv-01192-MN (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Oct 2024 – Mar 2025 148 days |
| Outcome | Plaintiff Win – Non-Infringement |
| Patents at Issue | |
| Accused Products | Sandoz Nintedanib 100 mg & 150 mg Capsules |
Case Overview
The Parties
⚖️ Plaintiff
Leading global generic pharmaceutical company and a division of Novartis, seeking to enter the nintedanib market with ANDA products.
🛡️ Defendant
Originator and patent holder of nintedanib (Ofev®), defending its valuable formulation patent portfolio against generic challengers.
Patents at Issue
This landmark Hatch-Waxman case involved two formulation patents covering nintedanib, a key active pharmaceutical ingredient:
- • US 9,907,756 — Capsule pharmaceutical dosage form for indolinone derivatives.
- • US 10,105,323 — Pharmaceutical dosage form for immediate release of an indolinone derivative.
Developing a generic pharmaceutical?
Check if your formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
On March 21, 2025, Chief Judge Maryellen Noreika entered a Final Judgment of Non-Infringement in favor of Sandoz on both Count I (‘756 patent) and Count II (‘323 patent). The court found that Sandoz’s manufacture, use, sale, offer for sale, and importation of its ANDA products “does not and would not constitute infringement, either direct or indirect, literally, or pursuant to the doctrine of equivalents” of either asserted patent. No monetary damages were awarded.
Key Legal Issues
The case resolved via a consent judgment, a negotiated legal instrument where both parties agreed to a binding court order of non-infringement. This provides Sandoz with a clear regulatory path without proceeding to full adjudication, covering both literal and doctrine of equivalents infringement for its ANDA No. 216915 products.
Developing a new drug formulation?
Learn from this case. Use AI to optimize your patent claims and avoid future litigation risks.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for Pharmaceutical Formulations
This case highlights critical IP risks in pharmaceutical formulation. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related formulation patents in this therapeutic space
- See which companies are most active in nintedanib patents
- Understand claim scope around suspension and immediate release
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic drug formulation.
- Input your formulation details or technical features
- AI identifies potentially blocking formulation patents
- Get actionable risk assessment report
High Risk Area
Formulations similar to branded nintedanib (Ofev®)
2 Key Patents
Specifically US ‘756 and US ‘323
Design-Around Options
Achieved through careful formulation development
✅ Key Takeaways
For Patent Attorneys & Litigators
Consent judgments on the merits provide stronger ANDA regulatory support than dismissals without prejudice.
Search related case law →The doctrine of equivalents carve-out in the judgment signals Sandoz’s formulation is substantively distinct from both asserted patent claims.
Explore precedents →For R&D Teams & Formulators
FTO analysis for generic formulations should account for specific claim language, especially on suspension vehicle and release mechanisms.
Start FTO analysis for my product →Early and thorough FTO analysis during generic formulation development reduces downstream litigation risk.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.
*🔗 Explore the case docket via PACER under Case No. 1:24-cv-01192-MN (D. Del.). Review patent details for US9907756B2 and US10105323B2 on Google Patents or the USPTO database.*